Back

Nimesh Pinnamaneni
•

Helixworks Technologies • 1m

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power

Anonymous 2

Hey I am on Medial • 1m

As someone who works in clinical diagnostics, I think people are missing what makes Molbio special. Their Truenat platform is genuinely revolutionary for developing markets. Traditional PCR requires stable electricity, climate control, and trained technicians. Truenat works on battery power in rural settings. This is why WHO endorsed it for TB testing - it brings molecular diagnostics to places Cepheid can't reach cost-effectively. Yes, COVID inflated their numbers, but their base business is solving a real problem. That said, 22,000Cr valuation is steep. I'd consider buying post-IPO after the inevitable correction, but the underlying technology has legs beyond the hype.

1 replies2 likes

Replies (1)

Nimesh Pinnamaneni
•

Helixworks Technologies • 1m

Yup their products are great for low-resource setting in LMICs. Big fan of this company. Amazing how they developed the tech indigenously and made a global play. Their automated DNA extraction is super useful too. Curious—do you have any info on how much their cartridges cost for various diseases? I’m working on a sequencing-based diagnostics assay and would love to chat. Please DM!

0 replies

Recommendations from Medial

Nimesh Pinnamaneni
•

Helixworks Technologies • 1m

10 replies40 likes

Nimesh Pinnamaneni
•

Helixworks Technologies • 28d

Looking to connect with folks in clinical diagnostics and molecular biology! I’m building a new clinical lab focused on infectious disease diagnostics powered by DNA sequencing — and would love to connect with people who have experience in: • Runni

0 replies2 likes

Nimesh Pinnamaneni
•

Helixworks Technologies • 1m

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren

0 replies2 likes

Nimesh Pinnamaneni

Making synthetic DNA... • 28d

🚨 The magic number: ₹800 Cr ⸻ VCs invest in businesses that can be big enough to return their entire fund. To get VCs interested, your startup must at least have the potential to reach ₹800 Cr+ in annual revenue or ₹8,000 Cr+ in market cap (assumi

0 replies6 likes